11
Dimarchi Richard Dennis, Glaesner Wolfgang, Millican Rohn Lee Junior, Vick Andrew Mark, Zhang Lianshan: Polyethelene glycol link glp-1 compounds. Eli Lilly And Company, Dimarchi Richard Dennis, Glaesner Wolfgang, Millican Rohn Lee Junior, Vick Andrew Mark, Zhang Lianshan, COX Gregory, November 4, 2004: WO/2004/093823 (59 worldwide citation)

The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositio ...


12
Paul Edward Aldrich, Argyrios Georgios Arvanitis, Rajagopal Bakthavatchalam, James Peter Beck, Robert Scott Cheeseman, Robert John Chorvat, Paul Joseph Gilligan, Carl Nicholas Hodge, Zelda Rakowitz Wasserman: 1N-alkyl-N-arylpyrimidinamines and derivatives thereof. Dupont Pharmaceuticals Company, Monte R Browder, Kenneth B Rubin, August 22, 2000: US06107301 (58 worldwide citation)

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppressi ...


13
Bernard Hulin, Janice C Parker: Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors. Pfizer, Peter C Richardson, Gregg C Benson, Robert T Ronau, March 23, 2004: US06710040 (53 worldwide citation)

The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, suc ...


14
Henry C Lin, Mark Pimentel: METHOD OF DIAGNOSING IRRITABLE BOWEL SYNDROME AND OTHER DISORDERS CAUSED BY SMALL INTESTINAL BACTERIAL OVERGROWTH BY DETECTING THE PRESENCE OF ANTI-SACCHAROMYCES CERIVISIAE ANTIBODIES (ASCA) IN HUMAN SERUM. Cedars Sinai Medical Center, Sidley Austin Brown & Wood, May 13, 2003: US06562629 (53 worldwide citation)

Disclosed is a method of diagnosing small intestinal bacterial overgrowth (SIBO), irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder (ADHD), or an autoimmune disease by sampling serum from a human subject having a suspected diagnosi ...


15
Henry C Lin, Mark Pimentel: Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions. Cedars Sinai Medical Center, Seth D Levy, Davis Wright Tremaine, May 23, 2006: US07048906 (48 worldwide citation)

Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory ...


16
Theoharis C Theoharides: Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin. KOS Pharmaceutical, July 15, 1997: US05648355 (47 worldwide citation)

A method for treating endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin, such as abdominal migraine and irritable bowel syndrome, entails administering a pharmacologically effective amount of a mast cell degranulation-blocking agent.


17
Ernesto Marcelo Dario Korenman, Tuvi Orbach, Bernard William Watson: Biofeedback apparatus for use in therapy. Ultramind International, Breiner & Breiner, February 15, 2000: US06026322 (46 worldwide citation)

Apparatus and a program designed to train the user to control one or more aspects of his or her psycho-physiological state is controlled by signals representative of a psycho-physiological parameter of the user, e.g. galvanic skin resistance. This may be detected by a sensor unit with two contacts o ...


18
Charles E Day: Method for treatment of irritable bowel syndrome. Gordon W Hueschen, January 10, 1995: US05380522 (44 worldwide citation)

A method of treating irritable bowel syndrome, including diarrhea, constipation, and pain aspects thereof, in a human patient, whereby the method involves the step of orally administering to the human patient an amount of an anion-binding polymer and a hydrophilic polymer, either simultaneously, con ...


19
Mase Toshiaki, Mitsuya Morihiro, Kobayashi Kensuke, Noguchi Kazuhito: Substituted heteroaromatic derivatives. Banyu Pharma, September 9, 1998: EP0863141-A1 (44 worldwide citation)

This invention provides substituted heteroaromatic ring derivatives which are represented by a general formula ÄIÜ below: Äin the formula, R and R may be same or different and each signifies hydrogen, halogen or lower alkyl; R signifies C3-C6 cycloalkyl or cycloalkenyl; R signifies a heteroaromatic ...


20
Wallace John L, Cirino Giuseppe, Caliendo Giuseppe, Sparatore Anna, Santagada Vincenzo, Fiorucci Stefano: Derivatives of 4- or 5-aminosalicylic acid. Antibe Therapeutics, Wallace John L, Cirino Giuseppe, Caliendo Giuseppe, Sparatore Anna, Santagada Vincenzo, Fiorucci Stefano, BENNETT JONES, November 30, 2006: WO/2006/125293 (42 worldwide citation)

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bo ...



Click the thumbnails below to visualize the patent trend.